United States Weight Loss Therapeutics Market to hit US$ 20.84 Billion by 2033: Pfizer's $10B Metsera Deal Challenges Novo Nordisk | Leading Companies are Novo Nordisk A/S, Eli Lilly, Pfizer, Rhythm Pharmaceuticals, Inc., CHEPLAPHARM GmbH

weight loss therapeutics market was valued at US$ 3.30 Billion in 2023. The global Weight Loss Therapeutics market size reached US$ 3.92 Billion in 2024 and is expected to reach US$ 20.84 Billion by 2033, growing at a CAGR of 20.6% during the forecast period 2025-2033.

DataM Intelligence has released its latest report on the "Weight Loss Therapeutics Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/weight-loss-therapeutics-market?kb

Top Weight Loss Drugs 2025-2026

✦ Wegovy® (semaglutide, Novo Nordisk)

✦ Zepbound® (tirzepatide, Eli Lilly)

✦ Mounjaro® (tirzepatide, Eli Lilly)

✦ Poviztra (oral semaglutide, Novo/Emcure, India)

✦ Orforglipron (oral GLP-1 in late-stage FDA review)

✦ Generic Saxenda® (liraglutide, Teva)

✦ Retatrutide, bimagrumab, MET-097i (Pfizer/Metsera), VK2735 (Viking Therapeutics) in pipeline

Latest M&A

Pfizer acquires Metsera: In a landmark deal valued up to $10 billion, Pfizer bought Metsera, a biotech developing next-gen oral and injectable incretin and amylin agonist therapeutics for weight loss-positioning Pfizer with a late-stage obesity portfolio alongside Novo Nordisk and Eli Lilly.​

Novo Nordisk completed multi-billion dollar acquisitions of Akero Therapeutics, furthering expansion in metabolic disease and obesity pharmacology.

Key Player:

Novo Nordisk A/S, Currax Pharmaceuticals LLC, Eli Lilly and Company, VIVUS LLC, Rhythm Pharmaceuticals, Inc., CHEPLAPHARM GmbH, GSK plc, KVK Tech, Inc., Teva Pharmaceutical Industries Ltd

Key Industry Developments:

In June 2025, Viking Therapeutics, Inc. launched its VANQUISH Phase 3 clinical program for VK2735, a dual GLP-1 and GIP receptor agonist. This milestone advances Viking's obesity pipeline, with VK2735 being developed in both oral and injectable forms to target metabolic disorders.

In March 2025, Eli Lilly & Co. introduced its anti-obesity drug Mounjaro (tirzepatide) in India, marking the country's first approved therapy for chronic weight management. Priced between ₹14,000-₹17,500 per month, Mounjaro provides a breakthrough treatment for obesity and related conditions.

Also in March 2025, Roche entered an exclusive collaboration and licensing deal with Zealand Pharma to develop petrelintide, an amylin analog for obesity treatment. The partnership aims to co-develop petrelintide both as a standalone therapy and in a fixed-dose combination with Roche's incretin candidate CT-388.

Forecast Projection:

The global Weight Loss Therapeutics market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.

Latest News & Market Launches

Major price cuts and broader access: November 2025: Novo Nordisk, Eli Lilly, and the White House struck deals to lower retail prices of Wegovy, Zepbound, and forthcoming oral GLP-1 therapies with "TrumpRx" pricing-cutting costs to $245/month for injectables and $149/month for some oral drugs for Medicare/Medicaid, and a $50 copay cap for Medicare patients.​

Market launches: Novo Nordisk and Emcure launched Poviztra (oral semaglutide) in India in November 2025; Eli Lilly's Mounjaro became India's top-selling drug by value, underscoring global demand for novel weight loss therapies.​

New generics: Teva launched the first-ever generic Saxenda® (liraglutide) for weight loss in August 2025 following FDA approval, increasing patient access.​

Leading pipeline drugs: Orforglipron (Eli Lilly oral GLP-1) submitted to FDA with expected March 2026 approval; phase III data for retatrutide (Lilly: triple agonist) expected in 2026 after phase II showed >20% mean weight loss; bimagrumab and tirzepatide combos are also in advanced trials

Market Intelligence Research Process:

The Weight Loss Therapeutics Market Report by DataM Intelligence offers a comprehensive analysis built on a mix of primary and secondary research. It explores key factors driving the industry, including government policies, market trends, competitive landscape, technological advancements, and upcoming innovations. This in-depth study uncovers both growth opportunities and potential challenges, helping businesses navigate market fluctuations and make data-driven decisions for sustainable success.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=weight-loss-therapeutics-market?kb

Key Segmentations:

By Therapeutics: (Prescription Drugs, Over-the-Counter, Natural Supplements, Others)

By Condition: (Obesity, Overweight, Others)

By Dosage Form: (Capsules, Tablets, Injectables, Others)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/weight-loss-therapeutics-market

FAQ's

Q1: How large is the Weight Loss Therapeutics Market?

Ans: The Weight Loss Therapeutics Market size was valued at US$ 3.92 Billion in 2024 and is projected to grow to US$ 20.84 Billion by 2033.

Q2: How quickly is the Weight Loss Therapeutics Market expanding?

Ans: The Weight Loss Therapeutics Market is forecasted to grow at a CAGR of 20.6% between 2025 and 2032, showing Annual growth momentum

Q3: Which regions are dominating the Weight Loss Therapeutics Market and which are fastest-growing?

Ans: North America dominating the Weight Loss Therapeutics market.

Q4: Why is Pfizer's $10 billion bid for Metsera making headlines?

Ans: Pfizer's fierce $10B battle with Novo for Metsera marks one of biotech's biggest showdowns, driven by the potential of Metsera's experimental obesity drugs - a slice of a market expected to hit $150 billion by the next decade.

Latest FDA & Reimbursement Developments

FDA approvals/expansions: FDA fast-tracked several new weight-loss agents and enabled use of oral GLP-1 for both obesity and cardiometabolic indications. Oral semaglutide (Novo) has a pending FDA decision for obesity.​

Reimbursement updates: Historic move-Medicare and Medicaid to reimburse all FDA-approved weight loss drugs (GLP-1s & others) for eligible patients starting mid-2026, with $50 copay caps for Medicare. TrumpRx cash platform further expands access price caps to broader US population.

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/weight-loss-therapeutics-market?kb

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Related reports

Weight loss stomach pump Market: https://www.datamintelligence.com/download-sample/weight-loss-stomach-pump-market?kb

Weight-Loss Devices Market: https://www.datamintelligence.com/download-sample/weight-loss-devices-market?kb

We!ght Loss Supplement Market: https://www.datamintelligence.com/download-sample/weight-loss-supplement-market?kb

Glucagon-like Peptide 1 (GLP-1) Analogues Market: https://www.datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?kb

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.